The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1619-7089
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma ; day:23 ; month:8 ; year:2016 ; pages:1-9
European journal of nuclear medicine and molecular imaging ; (23.8.2016), 1-9
- Urheber
-
Poulsen, Sidsel Højklint
- Beteiligte Personen und Organisationen
-
Urup, Thomas
Grunnet, Kirsten
Christensen, Ib Jarle
Larsen, Vibeke Andree
Jensen, Michael Lundemann
Rosenschöld, Per Munck af
Poulsen, Hans Skovgaard
Law, Ian
SpringerLink (Online service)
- DOI
-
10.1007/s00259-016-3494-2
- URN
-
urn:nbn:de:1111-2016092019265
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Poulsen, Sidsel Højklint
- Urup, Thomas
- Grunnet, Kirsten
- Christensen, Ib Jarle
- Larsen, Vibeke Andree
- Jensen, Michael Lundemann
- Rosenschöld, Per Munck af
- Poulsen, Hans Skovgaard
- Law, Ian
- SpringerLink (Online service)
Ähnliche Objekte (12)
Interstitial photodynamic therapy for newly diagnosed glioblastoma
Visualizing cellularity and angiogenesis in newly-diagnosed glioblastoma with diffusion and perfusion MRI and FET-PET imaging
Simultaneous boost radiotherapy versus conventional dose radiotherapy for patients with newly diagnosed glioblastoma: a multi-institutional analysis
Impact of time to initiation of radiotherapy on survival after resection of newly diagnosed glioblastoma
Impact of time to initiation of radiotherapy on survival after resection of newly diagnosed glioblastoma
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
Bench to bedside radiosensitizer development strategy for newly diagnosed glioblastoma
Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial
Newly Diagnosed IDH-Wildtype Glioblastoma and Temporal Muscle Thickness: A Multicenter Analysis
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial
RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study
A balanced score to predict survival of elderly patients newly diagnosed with glioblastoma
Interstitial photodynamic therapy for newly diagnosed glioblastoma
Visualizing cellularity and angiogenesis in newly-diagnosed glioblastoma with diffusion and perfusion MRI and FET-PET imaging
Simultaneous boost radiotherapy versus conventional dose radiotherapy for patients with newly diagnosed glioblastoma: a multi-institutional analysis
Impact of time to initiation of radiotherapy on survival after resection of newly diagnosed glioblastoma
Impact of time to initiation of radiotherapy on survival after resection of newly diagnosed glioblastoma
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
Bench to bedside radiosensitizer development strategy for newly diagnosed glioblastoma
Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial
Newly Diagnosed IDH-Wildtype Glioblastoma and Temporal Muscle Thickness: A Multicenter Analysis
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial
RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study
A balanced score to predict survival of elderly patients newly diagnosed with glioblastoma
Interstitial photodynamic therapy for newly diagnosed glioblastoma
Visualizing cellularity and angiogenesis in newly-diagnosed glioblastoma with diffusion and perfusion MRI and FET-PET imaging
Simultaneous boost radiotherapy versus conventional dose radiotherapy for patients with newly diagnosed glioblastoma: a multi-institutional analysis
Impact of time to initiation of radiotherapy on survival after resection of newly diagnosed glioblastoma
Impact of time to initiation of radiotherapy on survival after resection of newly diagnosed glioblastoma
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
Bench to bedside radiosensitizer development strategy for newly diagnosed glioblastoma
Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial
Newly Diagnosed IDH-Wildtype Glioblastoma and Temporal Muscle Thickness: A Multicenter Analysis
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial
RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study